HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases Thea Eline Hetland1

Virchows Archiv

Volumn 460, Issue 5, 2012, Pages 505-513

  Holth, Arild ^a   Kærn, Janne ^a   Flørenes, Vivi Ann ^c   Tropé, Claes G ^a,b   Davidson, Ben ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO METROPOLITAN UNIVERSITY   (Norway)

Author keywords

Effusions; HMGA2; Metastasis; Ovarian carcinomas; Survival

Indexed keywords

CLAUDIN 7; HIGH MOBILITY GROUP A2 PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; NESTIN; PACLITAXEL; PLATINUM; PROTEIN SIP1; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EFFUSION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM EXUDATE; PLEURA EFFUSION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HMGA2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863725713     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1228-9     Document Type: Article

References (37)

1. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135-166 (Pubitemid 39658498)
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J Clin Oncol 20:1248-1259 (Pubitemid 34177431)
4. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943-953
5. Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinthaller A, Vergote I, Pignata S, Ferrero A (2009) A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG) J Clin Oncol 27:18 s (suppl; abstr LBA5509).
6. Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A (2010) Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 10:81-88
7. Cleynen I, Van De Ven WJ (2008) The HMGA proteins: a myriad of functions (review). Int J Oncol 32:289-305 (Pubitemid 351188295)
8. Fedele M, Fusco A (2010) HMGA and cancer. Biochim Biophys Acta 1799:48-54
9. Mahajan A, Liu Z, Gellert L, Zou X, Yang G, Lee P, Yang X, Wei JJ (2010) HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 23:673-681
10. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study Group, Gertig D, DeFazio A, Bowtell DD (2008) Novelmolecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(5198)
11. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Group Australian Ovarian Cancer Study, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6:e18064
12. Davidson B (2007) Biological characteristics of cancers involving the serosal cavities. Crit Rev Oncog 13:189-227 (Pubitemid 351239093)
13. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME (2007) Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 6:2585-2590 (Pubitemid 350224037)
14. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME (2007) Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 104:11400-11405 (Pubitemid 47175152)
15. Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei JJ (2011) HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated though regulation of EMT genes. Cancer Res 71:349-359
16. Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P, Liu J (2010) HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 34:18-26
17. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O (2008) HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123:348-356 (Pubitemid 351842019)
18. Vang R, Shih IeM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16:267-282
19. Davidson B, Nielsen S, Christensen J, Asschenfeldt P, Berner A, Risberg B, Johansen P (2001) The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 25:1405-1412 (Pubitemid 33022056)
20. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753 (Pubitemid 24349373)
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
22. Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B (2005) Snail, Slug, and Smadinteracting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103:1631-1643 (Pubitemid 40490024)
23. Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Reich R (2006) Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 449:520-528 (Pubitemid 44722320)
24. Kleinberg L, Holth A, Trope' CG, Reich R, Davidson B (2008) Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol 39:747-757 (Pubitemid 351618309)
25. Davidson B, Shih IM, Wang TL (2008) Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. Hum Pathol 39:1630-1636
26. Vaksman O, Tuft Stavnes H, Kærn J, Trope' CG, Davidson B, Reich R (2011) miRNA profiling along tumor progression in ovarian carcinoma. J Cell Mol Med 15:1593-1602
27. Park JT, Chen X, Tropè CG, Davidson B, IeM S, Wang TL (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177:1087-1094
28. Hetland TE, Hellesylt E, Flørenes AV, Tropé C, Davidson B, Kærn J (2011) Class III ?-tubulin expression in advanced state serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 42:1019-1026
29. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5:e232
30. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E (2007) Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109-1123 (Pubitemid 350235025)
31. Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Trope CG, Van de Putte G, Nesland JM (2000) Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma -diagnostic and prognostic implications. Clin Exp Metastasis 18:197-202 (Pubitemid 32165254)
32. Tzatsos A, Bardeesy N (2008) Ink4a/Arf regulation by let-7b and Hmga2: a genetic pathway governing stem cell aging. Cell Stem Cell 3:469-470
33. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890
34. Kalluri R,Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428
35. Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropè CG, Kristensen GB, Bryne M, Ann Florenes V (2000) E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 192:460-469
36. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH, Moustakas A (2008) HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283:33437-33446
37. Lu L, Schwartz P, Scarampi L, Rutherford T, Canuto EM, Yu H, Katsaros D (2011) MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management. Gynecol Oncol 122:366-371